阿昔单抗

阿昔单抗在接受直接冠状动脉介入治疗的急性心肌梗死患者中的早期应用

Early abciximab administration in acute myocardial infarction treated with primary coronary intervention

接受替非罗班治疗的患者的早期结果和接受阿昔单抗治疗的患者相比，不存在显著性差异。

There is no apparent difference in early outcomes of patients treated with eptifibatide compared with patients treated with abciximab .

在3～24h时间窗内采用阿昔单抗治疗缺血性卒中的MRI引导的开放性试验

MRI-guided , open trial of abciximab for ischemic stroke within a 3-to 24-hour window

背景&来自随机对照试验的汇萃数据表明，因急性ST段抬高型心肌梗塞行直接PCI术后的患者，使用阿昔单抗可以提高生存率。

Background : Pooled data from randomized controlled trials suggest that the use of abciximab may be associated with a survival advantage in patients undergoing primary PCI for acute STEMI .

目的探讨血小板Ⅱb/Ⅲa受体拮抗剂阿昔单抗在急性心肌梗死直接经皮冠状动脉腔内成形术（PTCA）术中应用的安全性，合理性和对PTCA术后缺血并发症及预后的影响。

Objectives To investigate the safety and feasibility of using platelet ⅱ b / ⅲ a receptor antagonist during direct percutaneous tranluminal coronary angioplasty ( PTCA ) and its effect on ischemic complications following PTCA in patients with acute myocardial infarction ( AMI ) .

血小板-单核细胞聚集可预测经皮冠状动脉介入后肌钙蛋白增高，且可被阿昔单抗抑制

Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab

替罗非班加西罗莫司洗脱支架与阿昔单抗加裸金属支架治疗急性心肌梗死的随机对比试验

Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction : A randomized trial

阿昔单抗诱发血小板减少症及其治疗

Abciximab-induced thrombocytopenia and its treatment

目的：本前瞻性、随机试验旨在评价早期使用阿昔单抗对血管造影及左室功能参数的影响。

Objectives : This prospective randomized trial evaluates the impact of early abciximab administration on angiographic and left ventricular function parameters .

然而，却有相当比例的患者的治疗使用了替非罗班&具有阿昔单抗的部分药理学特性。

However , a large proportion of patients in the community are treated with eptifibatide , an agent that shares some but not all pharmacological properties with abciximab .